Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib study of CL184 safety, tolerability, neutralizing activity, and pharmacokinetics in healthy volunteers
ISRCTN12693237Phase 2Completed
- Sponsor
- Crucell
- Start
- Apr 2007
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of CL184 and Rabies vaccine in rabies (2 arms), sponsored by Crucell. Primary endpoint: Safety and tolerability. Started Apr 2007; status: completed.
02
Drugs
CL184Rabies vaccine
03
Conditions
rabies
Beyond the preview
Go deeper on ISRCTN12693237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12693237.